evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,919 questions · 13,869 findings · 2,177 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 13,869 · 100%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or

5a.Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation

The review found no eligible studies for this question.

1 finding from 1 review

Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or

5b. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to alternative treatment for the prevention of reintubation · prevention of reintubation

The review found no eligible studies for this question.

1 finding from 1 review

Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or

5c. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the prevention of reintubation · prevention of reintubation

The review found no eligible studies for this question.

1 finding from 1 review

Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or

Chronic lung disease · treatment of apnea

The review found no eligible studies for this question.

3 findings from 1 review

Summary of findings table ‐ Intermittent PEG‐asparaginase treatment (8 doses, 1000 IU/m2, IM) vs continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM)

Overall survival ‐ not reported · children and adolescents (< 18 years of age) with first‐line ALL

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV)

Thromboembolism · children and adolescents (< 18 years of age) with first‐line ALL

The review found no eligible studies for this question.

1 finding from 1 review